口腔黏膜黑色素瘤人源性移植瘤模型的建立及鉴定

doi:10.19438/j.cjoms.2017.06.001

中国口腔颌面外科杂志 ›› 2017, Vol. 15 ›› Issue (6): 481-487.doi: 10.19438/j.cjoms.2017.06.001

口腔黏膜黑色素瘤人源性移植瘤模型的建立及鉴定

陶文杰¹, 韩永¹, 周榕¹, 石超吉¹, 洪多¹, 李江², 孙树洋¹, 张志愿¹

1.上海交通大学医学院附属第九人民医院·口腔医学院口腔颌面-头颈肿瘤科,
2.口腔病理科,上海市口腔医学重点实验室,上海 200011

收稿日期:2017-03-19 修回日期:2017-07-05 出版日期:2017-11-20 发布日期:2017-12-21
通讯作者: 张志愿,E-mail：zhzhy0502@163.com
作者简介:陶文杰（1988-）,男,硕士研究生,E-mail：wj_tao@hotmail.com
基金资助:
国家自然科学基金 (81572656)

Establishment and validation of patient-derived xenograft model of oral mucosal melanoma

TAO Wen-jie¹, HAN Yong¹, ZHOU Rong¹, SHI Chao-ji¹, HONG Duo, LI Jiang², SUN Shu-yang¹, ZHANG Zhi-yuan¹

1.Department of Oromaxillofacial Head and Neck Oncology, 2.Department of Oral Pathology, Shanghai Ninth People's Hospital, College of Stomatology, Shanghai Jiao Tong University School of Medicine; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2017-03-19 Revised:2017-07-05 Online:2017-11-20 Published:2017-12-21

摘要/Abstract

摘要： 目的建立和鉴定口腔黏膜黑色素瘤（oral mucosal melanoma,OMM）人源性移植瘤（patient-derived xenograft,PDX）模型。方法将4例原发性口腔黏膜黑色素瘤组织移植于免疫缺陷裸鼠皮下,观察并记录裸鼠成瘤情况,待移植瘤稳定生长后进行传代;利用H-E染色观察原发瘤和移植瘤的组织病理学特征,应用免疫组织化学染色检测黑色素瘤标志物HMB-45、Melan-A、S-100及Ki-67在两者组织的表达水平。结果 4例口腔黏膜黑色素瘤组织皮下移植成功并序列传代;H-E和免疫组织化学染色显示,移植瘤在组织病理形态和4个标志物表达情况上与原发瘤保持一致。结论本研究成功建立4例口腔黏膜黑色素瘤人源性移植瘤模型,传代移植瘤保留了原发瘤的组织病理学和分子特征,可为口腔黏膜黑色素瘤研究提供理想的临床前动物模型。

关键词: 口腔黏膜黑色素瘤, 人源性移植瘤模型, 裸鼠

Abstract: PURPOSE: To establish and validate patient-derived xenograft (PDX) model of oral mucosal melanoma (OMM). METHODS: Four primary OMM specimens were implanted into immune-deficient nude mice subcutaneously, the mice were evaluated for tumor growth, stable xenograft tumor models and were passaged. Histopathological characteristics were observed by H-E staining. OMM-associated clinical markers (HMB-45, Melan-A, S-100 and Ki-67) were detected by immunohistochemistrical staining. RESULTS: OMM samples from 4 patients were implanted subcutaneously and passaged for expansion successfully. Histopathologically and immunohistochemistrically, PDX models showed similar morphology and HMB-45, Melan-A, S-100 and Ki-67 protein expression to the primary tumor. CONCLUSIONS: Four xenograft models were successfully established, in which the histopathological and molecular features of the primary tumors are preserved through passaging, which provid promising preclinical models for translational research of OMM.

Key words: Oral mucosal melanoma, Patient-derived xenograft model, Nude mice

中图分类号:

R739.8

陶文杰, 韩永, 周榕, 石超吉, 洪多, 李江, 孙树洋, 张志愿. 口腔黏膜黑色素瘤人源性移植瘤模型的建立及鉴定[J]. 中国口腔颌面外科杂志, 2017, 15(6): 481-487.

TAO Wen-jie, HAN Yong, ZHOU Rong, SHI Chao-ji, HONG Duo, LI Jiang, SUN Shu-yang, ZHANG Zhi-yuan. Establishment and validation of patient-derived xenograft model of oral mucosal melanoma[J]. China J Oral Maxillofac Surg, 2017, 15(6): 481-487.

参考文献

[1] Yang X, Ren GX, Zhang CP, et al. Neck dissection and post-operative chemotherapy with dimethyl triazeno imidazole carboxamide and cisplatin protocol are useful for oral mucosal melanoma[J]. BMC Cancer, 2010, 10: 623.
[2] 李丽, 孔燕, 李海夫, 等. 262例中国人黑色素瘤C-KIT基因扩增分析 [J]. 临床肿瘤学杂志, 2010, 15(5): 385-389.
[3] 吴云腾, 任国欣, 孙沫逸, 等. 中国头颈黏膜黑色素瘤临床诊治专家共识 [J]. 中国口腔颌面外科杂志, 2015, 13(3): 262-269.
[4] Sun CZ, Chen YF, Jiang YE, et al. Treatment and prognosis of oral mucosal melanoma [J]. Oral Oncol, 2012, 48(7): 647-652.
[5] 郭伟, 任国欣, 王新, 等. 口腔颌面-头颈恶性黑色素瘤综合治疗探索及进展[C]. 上海：国际暨全国第十一届头颈肿瘤学术大会论文集, 2011: 36-39.
[6] Tentler JJ, Tan AC, Weekes CD, et al. Patient-derived tumour xenografts as models for oncology drug development [J]. Nat Rev Clin Oncol, 2012, 9(6): 338-350.
[7] Hidalgo M, Amant F, Biankin AV, et al. Patient-derived xenograft models: an emerging platform for translational cancer research [J]. Cancer Discov, 2014, 4(9): 998-1013.
[8] Aparicio S, Hidalgo M, Kung AL. Examining the utility of patient-derived xenograft mouse models [J]. Nat Rev Cancer, 2015, 15(5): 311-316.
[9] Stewart EL, Mascaux C, Pham NA, et al. Clinical utility of patient-derived xenografts to determine biomarkers of prognosis and map resistance pathways in EGFR-mutant lung adenocarcinoma [J]. J Clin Oncol, 2015, 33(22): 2472-2480.
[10] Gao H, Korn JM, Ferretti S, et al. High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response [J]. Nat Med, 2015, 21(11): 1318-1325.
[11] Bertotti A, Migliardi G, Galimi F, et al. A molecularly annotated platform of patient-derived xenografts ("xenopatients") identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer [J]. Cancer Discov, 2011, 1(6): 508-523.
[12] Marangoni E, Poupon MF. Patient-derived tumour xenografts as models for breast cancer drug development [J]. Curr Opin Oncol, 2014, 26(6): 556-561.
[13] Laurent C, Gentien D, Piperno-Neumann S, et al. Patient-derived xenografts recapitulate molecular features of human uveal melanomas [J]. Mol Oncol, 2013, 7(3): 625-636.
[14] Sun S, Zhang Z. Patient-derived xenograft platform of OSCC: a renewable human bio-bank for preclinical cancer research and a new co-clinical model for treatment optimization [J]. Front Med, 2016, 10(1): 104-110.
[15] Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia [J]. Annu Rev Pathol, 2014, 9: 239-271.
[16] Shultz LD, Goodwin N, Ishikawa F, et al. Human cancer growth and therapy in immunodeficient mouse models [J]. Cold Spring Harb Protoc, 2014, 2014(7): 694-708.
[17] 李克娟, 黄昊, 高苒. 人源肿瘤异种移植模型在精准肿瘤医学中的研究进展[J]. 中国比较医学杂志, 2017, 27(1): 91-98.
[18] Jin K, Teng L, Shen Y, et al. Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review [J]. Clin Transl Oncol, 2010, 12(7): 473-480.
[19] 刘情, 郑琳, 张灏. 人源性肿瘤组织异种移植模型的研究进展 [J]. 转化医学杂志, 2014, 3(2): 65-68.
[20] Siolas D, Hannon GJ. Patient-derived tumor xenografts: transforming clinical samples into mouse models [J]. Cancer Res, 2013, 73(17): 5315-5319.
[21] Dong X, Guan J, English JC, et al. Patient-derived first generation xenografts of non-small cell lung cancers: promising tools for predicting drug responses for personalized chemotherapy [J]. Clin Cancer Res, 2010, 16(5): 1442-1451.
[22] Julien S, Merino-Trigo A, Lacroix L, et al. Characterization of a large panel of patient-derived tumor xenografts representing the clinical heterogeneity of human colorectal cancer [J]. Clin Cancer Res, 2012, 18(19): 5314-5328.
[23] Zhang X, Claerhout S, Prat A, et al. A renewable tissue resource off phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models [J]. Cancer Res, 2013, 73(15): 4885-4897.
[24] Landis MD, Lehmann BD, Pietenpol JA, et al. Patient-derived breast tumor xenografts facilitating personalized cancer therapy [J]. Breast Cancer Res, 2013, 15(1): 201.
[25] Ricci F, Bizzaro F, Cesca M, et al. Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations [J]. Cancer Res, 2014, 74(23): 6980-6990.
[26] Girotti MR, Gremel G, Lee R, et al. Application of sequencing, liquid biopsies, and patient-derived xenografts for personalized medicine in melanoma [J]. Cancer Discov, 2016, 6(3):286-299.
[27] Townsend EC, Murakami MA, Christodoulou A, et al. The public repository of xenografts enables discovery and randomized Phase II-like trials in mice [J]. Cancer Cell, 2016, 29(4): 574-586.
[28] Bruna A, Rueda OM, Greenwood W, et al. A biobank of breast cancer explants with preserved intra-tumor heterogeneity to screen anticancer compounds [J]. Cell, 2016, 167(1): 260-274.
[29] Nardella C, Lunardi A, Patnaik A, et al. The APL paradigm and the "co-clinical trial" project[J]. Cancer Discov, 2011, 1(2): 108-116.

口腔黏膜黑色素瘤人源性移植瘤模型的建立及鉴定

Establishment and validation of patient-derived xenograft model of oral mucosal melanoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 2

编辑推荐

Metrics

本文评价

[1]	洪多, 顾子悦, 李江, 张志愿. 阿西替尼对人口腔黏膜黑色素瘤裸鼠移植瘤血管生成拟态的作用探讨[J]. 中国口腔颌面外科杂志, 2018, 16(4): 296-301.
[2]	张旭;方其根;李振宁;刘法昱;孙长伏. 裸鼠皮下种植性人头颈鳞癌模型的建立 [J]. 中国口腔颌面外科杂志, 2013, 11(5): 395-398.